Evidence map›Paper›PMID 27119078›Full record

ReviewBioMed research international2016

Ocular Complications of Diabetes and Therapeutic Approaches.

Victoria J Vieira-Potter, Dimitrios Karamichos, Darren J Lee

4 registry-linked trialsAbstract readReview
In one paragraph

Review in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04980144 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Four-week Randomized Control, Single Masked Pilot Study.

TypeinterventionalSponsorHe Eye HospitalRan2023 to 2023Enrolled101ConditionsDiabetic Eye ProblemsArms3% Diquafosol tetrasodium, 0.1% hyaluronate
NCT05193331 naunknown statusnot on this mapstarted 2023, after this paper: background citation

3% Diquafosol Topical Ophthalmic Solution in Diabetic Patients With Dry Eye

TypeinterventionalSponsorHe Eye HospitalRan2023 to 2023Enrolled70ConditionsDiabetic Eye ProblemsArms3% Diquafosol tetrasodium
NCT05682547 nacompletednot on this mapstarted 2022, after this paper: background citation

A Single Center, Randomized, Controlled Trial Comparing the Clinical Efficacy of 3% Diquafosol Tetrasodium and 0.1 % Hyaluronic Acid 0.1% in Diabetic Patients With Dry Eye Disease

TypeinterventionalSponsorHe Eye HospitalRan2022 to 2023Enrolled99ConditionsDiabetic Eye ProblemsArms3% Diquafosol tetrasodium, 0.1% hyaluronate
NCT06218992 unknown statusnot on this mapstarted 2023, after this paper: background citation

Corneal and Tear Film Changes in Chinese Patients With Type 2 Diabetes: a Cross-sectional Controlled Study

TypeobservationalSponsorHe Eye HospitalRan2023 to 2024Enrolled80ConditionsDry Eye Disease, Tear Film, Corneal Nerve
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Corneal Epithelial Changes in Diabetic Patients: A Review.International journal of molecular sciences · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Victoria J Vieira-PotterDepartment of Nutrition & Exercise Physiology, University of Missouri, Columbia, MO 65211, USA.
Dimitrios KaramichosDepartment of Cell Biology, Dean McGee Eye Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Ophthalmology, Dean McGee Eye Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Darren J LeeDepartment of Ophthalmology, Dean McGee Eye Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Microbiology and Immunology, Dean McGee Eye Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is a metabolic disease defined by elevated blood glucose (BG). DM is a global epidemic and the prevalence is anticipated to continue to increase. The ocular complications of DM negatively impact the quality of life and carry an extremely high economic burden. While systemic control of BG can slow the ocular complications they cannot stop them, especially if clinical symptoms are already present. With the advances in biodegradable polymers, implantable ocular devices can slowly release medication to stop, and in some cases reverse, diabetic complications in the eye. In this review we discuss the ocular complications associated with DM, the treatments available with a focus on localized treatments, and what promising treatments are on the horizon.

Indexed as

Blood GlucoseDiabetes ComplicationsDiabetic RetinopathyEyeGlaucomaHumansInsulinMacular EdemaQuality of LifeRisk FactorsBlood GlucoseInsulin

Identifiers

PMID27119078
PMCPMC4826913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.